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Abstract 
Ghrelin, a hormone whose levels increase during food deprivation, plays a pivotal role in the regulation of food 
intake, energy metabolism and storage, as well as in insulin sensitivity. Here, we investigated the effects of acyl-
ghrelin neutralization with the acyl-ghrelin-binding compound NOX-B11(2) during the fasting-refeeding cycle. Our 
data demonstrate that ghrelin neutralization with NOX-B11(2) impairs recuperation of lost body weight after food 
deprivation. Analysis of enzymes involved in glucose and lipid metabolism in liver of fed, fasted and refed rats 
revealed that neutralization of acyl-ghrelin resulted in minor decreases in the enzymes of glycolytic and lipogenic 
pathways during fasting. However, during refeeding these enzymes as well as glycogen levels recovered more slowly 
when acyl-ghrelin was blocked. The high levels of ghrelin in response to food deprivation may contribute to an 
adequate decrease in hepatic glycolytic and lipogenic enzymes and aid in the recovery of body weight and energetic 
reserves once food becomes available after the fasting period. 
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1. Introduction 
Energy homeostasis is a complex and tightly regulated process under control of neural and endocrine 
inputs. The survival of animals is intimately linked with the drive to find and accumulate food. It has been 
hypothesized that the scarcity of food throughout evolution favored dominant genetic pathways leading to 
increased caloric intake over mechanisms that cause reduction in energy intake (Ames, 2006). However, 
currently in Western societies obesity and its co-morbidities are the fastest growing health problem. 
Available pharmaceuticals have poor efficacy and are associated with undesirable side effects, 
emphasizing the need for new therapies (Hofbauer et al., 2007). 
In the last decade, ghrelin, a hormone secreted predominantly from the stomach, has attracted much 
attention due to its orexigenic effects as well as its function in mediating body weight gain and adiposity, 
demonstrated both in humans and rodents (Nakazato et al., 2001, Sangiao-Alvarellos et al., 2009, 
Theander-Carrillo et al., 2006, Tschop et al., 2000, Wren et al., 2001a and Wren et al., 2001b). Ghrelin 
circulates in the bloodstream in two different forms: acylated (AG) and unacylated (UAG). AG has a 
unique feature: a posttranslational esterification of a fatty acid (n-octanoic or, to a lesser extent, n-
decanoic) on serine at position three. It acts as the endogenous ligand of the growth hormone 
secretagogue receptor (GHSR) ( Kojima et al., 1999, Kojima et al., 2001a, Kojima et al., 
2001b and Nakazato et al., 2001) and its acylation is considered necessary for its actions via GHSR1a (the 
functional variant of GHSR) ( Howard et al., 1996 and Kojima et al., 1999). Recently, several groups 
identified ghrelin O-acyltransferase (GOAT), a membrane-bound enzyme that transfers octanoate from 
octanoyl CoA to serine-3 of ghrelin, forming an acyl ester ( Gutierrez et al., 2008 and Yang et al., 2008) 
and a recent study observed that GOAT links dietary lipids with the endocrine control of energy balance ( 
Kirchner et al., 2009). 
Despite much pharmacological data, the evidence for a physiological role of ghrelin in the control of 
appetite is still less clear. Mice with targeted deletions in either the gene for ghrelin or the GHSR as well 
as transgenic models exhibit an essentially normal metabolic phenotype when fed a regular chow diet, 
suggesting ghrelin may have a redundant role in the regulation of food intake (Ariyasu et al., 2005, 
Asakawa et al., 2005, Iwakura et al., 2005, Longo et al., 2008, Pfluger et al., 2008, Sun et al., 2003, Sun 
et al., 2006 and Sun et al., 2008). Nevertheless, the current body of evidence implicates ghrelin to play an 
important role in the control of glucose and lipid homeostasis (Broglio et al., 2001, Broglio et al., 2003, 
Vestergaard et al., 2008a, Vestergaard et al., 2008b and Zhao et al., 2010). 
Several studies show that treatment with ghrelin induces hyperglycemia and reduces insulin secretion 
(Broglio et al., 2001 and Cui et al., 2008). Moreover, it was found that a relation between ghrelin levels 
and insulin resistance exists (Gauna et al., 2004, Pacifico et al., 2009 and Vestergaard et al., 2008b). 
Altered plasma ghrelin levels are associated with insulin resistance in healthy, overweight and obese 
humans, and are thought to contribute to the association of insulin resistance and metabolic syndrome 
(Pacifico et al., 2009, St-Pierre et al., 2007 and Yada et al., 2008). 
Furthermore, ghrelin administration induces lipid storage and synthesis by promoting mRNA 
expression of fat storage-promoting enzymes in white adipose tissue (WAT) and liver, such as lipoprotein 
lipase (LPL), acetyl-CoA carboxylase alpha (ACCα), fatty acid synthase (FAS), and stearoyl-CoA 
desaturase-1 (SCD-1). In contrast, ghrelin inhibits lipid oxidation, decreasing activity and gene expression 
of the liver isoform of carnitine palmitoyltransferase 1 (CPT1A) (Barazzoni et al., 2005, Sangiao-
Alvarellos et al., 2009 and Theander-Carrillo et al., 2006). 
These findings and the observations that circulating ghrelin levels are increased prior to a meal and 
during food deprivation and caloric restriction, as well as in disease states such as anorexia and cachexia, 
but reduced after a meal and in obesity (Ikezaki et al., 2002, Liu et al., 2008, Shiiya et al., 2002, Tschop et 
al., 2001a, Tschop et al., 2001b, Van der Lely et al., 2004 and Yang et al., 2007), strongly implicate 
ghrelin being involved in the regulatory processes controlling meal initiation, priming metabolic 
pathways and leading to more efficient calorie storage. 
The aim of this study was to block acyl-ghrelin in order to investigate the metabolic adjustments 
during the fasting-refeeding cycle on glucose and lipid metabolism in the liver, the principal tissue of 
intermediary metabolism. Protein and mRNA levels as well as enzyme activities of the main enzymes 
involved in glucose and lipid metabolism were assessed. The neutralization of AG was accomplished by 
using the compound NOX-B11(2), an l-RNA-based antagonist (also called a Spiegelmer) of ghrelin. 
NOX-B11(2) does not interact with the ghrelin receptor, but is highly specifically binding the bioactive n-
octanoylated form of ghrelin itself. Moreover this compound neutralizes other types of acylated ghrelin 
like decanoyl-ghrelin (data not show, decenoyl-ghrelin was not tested). It blocks the biological effect by 
preventing ghrelin's activation of the endogenous receptor ( Helmling et al., 2004). The effects of ghrelin 
neutralization with NOX-B11(2) and related compounds on growth hormone secretion, food intake and 
body weight gain in diet-induced obese mice were previously demonstrated ( Helmling et al., 2004, 
Kobelt et al., 2006 and Shearman et al., 2006). 
Our data suggest that ghrelin has an essential role in body weight recovery after prolonged fasting. 
Moreover, neutralization of ghrelin impairs the normal decrease in lipogenic and glycolytic enzymes in 
the liver during fasting. Upon availability of food following a fasting period, the recovery of energetic 
reserves and metabolic pathways is compromised when ghrelin is neutralized. 
2. Materials and methods 
2.1. Animals and compounds 
All experiments and animal protocols involved in this study were reviewed and approved by the Ethics 
Committees of the UDC and CHUAC, in accordance with EU Normative for the use of experimental 
animals. Male Wistar rats (2–3 months old; body weight: 378 ± 5 g) were housed in a temperature 
controlled room, with a 12 h light, 12 h dark cycle (lights from 08:00 to 20:00 h). All rats were provided 
with ad libitum access to water. 
Acyl-ghrelin was purchased from Bachem (Bachem, Switzerland). Spiegelmer (SPM) NOX-B11(2) 
and the non-functional control SPM were synthesized at NOXXON Pharma AG using standard 
phosphoramidite chemistry. NOX-B11(2) is a derivative of SPM NOX-B11 whose selection has been 
described previously (Helmling et al., 2004). It was designed to bind specifically to acylated (bioactive) 
ghrelin, thus preventing the hormone from activating the GHSR1a (Helmling et al., 2004 and Shearman et 
al., 2006).  
2.2. Effects of acute ghrelin treatment on food intake in animals treated with anti ghrelin SPM NOX-
B11(2) 
To study the efficacy of NOX-B11(2) counteracting acyl-ghrelin, male Wistar rats fed ad libitum were 
intraperitoneally (IP) injected with vehicle (saline, n = 7), NOX-B11(2) (15 or 30 mg/kg, n = 7), or 
control SPM (30 mg/kg, n = 7) at 9:00 a.m. Two hours later, at 11:00 a.m. the animals were injected with 
saline or ghrelin (25 μg/rat, IP). Cumulative food intake was measured 2 h after treatment at 1:00 p.m. 
2.3. Fasting and fasting-refeeding trials 
In order to clarify the influence of acyl-ghrelin neutralization on hepatic glucose and lipid metabolism 
during the fasting-refeeding cycle, rats were fasted for 48 h or fasted and refed for 24 h or 48 h. Every 
24 h animals (eight rats per group) were injected intraperitoneally with NOX-B11(2) (30 mg/kg, IP) or 
control SPM (30 mg/kg, IP). The first injection was given once food had been removed. During the 
refeeding period, food was restricted to 80% of the daily amount of food ingested by the animals when 
given ad libitum access. Food was provided daily and both groups ate all the food offered. This refeeding 
regimen was chosen as it was expected to lead to a more pronounced effect, if ghrelin neutralization 
affects the utilization of nutrients. The regimen of treatment is illustrated in Fig. 1. 
 
 
 
Fig. 1. Schematic representation of treatments of the animals. 
Rats were sacrificed by cervical dislocation and trunk blood was extracted. Livers were dissected, 
divided in parts, and stored at −80 °C until further processing or homogenized with a motor pestle in ice-
cold buffer containing 50 mM Tris–HCl (pH 7.4), 250 mM sucrose, 1 mM ethylenediaminetetraacetic 
acid, 1 mM dithiothreitol, 100 mM NaF and protease inhibitor cocktail (Roche). Subsequently, 
homogenates were centrifuged for 10 min at 3000 rpm and the supernatant was extracted and used for 
studies of CPT1 activity.  
2.4. Plasma measurements 
Insulin levels were measured by a commercially available radioimmunoassay (Linco Research Inc.) 
according to the manufacturer's specifications. Plasma acyl-ghrelin levels were measured by ELISA 
according to the manufacturer's instructions (Millipore). Plasma glucose, lactate and triglyceride levels 
were assessed using a commercial kit based on a colorimetric method (Glucose, lactate and Triglyceride 
Spinreact). Plasma GH concentrations were determined by double antibody RIA using materials supplied 
by the National Hormone Pituitary Program, as described previously (Seoane et al., 2004). 
2.5. Real-time quantitative PCR 
mRNA levels of ACCα, FAS, SCD-1 and CPT1A were studied by real-time PCR (Roche) using specific 
primers and probes (Table 1). All reactions were carried out using the following cycling parameters: 
50 °C for 2 min, 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. For data 
analysis, the input value of the target gene was standardized to the 18S value for each sample. Data were 
expressed in comparison with the average value for the fed rats. 
Table 1. Primer sequences used for real-time PCR. 
Gene Accession number 
  
    
ACCα NM_022193 Forward 5′-TGGGCGGGATGGTCTCTTT-3′ 
Reverse 5′-AGTCGCAGAAGCAGCCCATT-3′ 
Probe FAM-5′-ACCTTTGAAGATTTCGTCAGGATCTTTGATGA-3′-TAMRA 
FAS NM_017332 Forward 5′-GACATTTCATCAGGCCACC-3′ 
Reverse 5′-CCTCTAGCAGCCGCACCTC-3′ 
Probe FAM-5′-CTGCCCAGGACAGGAACCG-3′-TAMRA 
SCD-1 NM_139192.2 Forward 5′-TGCCAGAGGGAATAGGGAAA-3′ 
Reverse 5′- CTCTCCCATCCTTACTTACAAACCA-3′ 
Probe FAM-5′-TCACCTTGAGAGAAGAATTAGCACGCACGG-3′-TAMRA 
CPT1A NM_031559 Forward 5′-ATGACGGCTATGGTGTCTCC -3′ 
Reverse 5′-TCATGGCTTGTCTCAAGTGC -3′ 
Probe FAM-5′-TGAGACAGACTCAGACCGCT-3′-TAMRA 
    
 
2.6. Western blotting 
Liver samples were homogenized in 10 volumes ice-cold buffer containing 50 mM Tris–HCl (pH 7.4), 
250 mM sucrose, 1 mM EDTA, 1 mM DTT, 100 mM NaF and protease inhibitor cocktail (Roche). For 
each sample, total protein lysates from liver (20 μg) were subjected to SDS-PAGE, electrotransferred on a 
polyvinylidene difluoride membrane and probed with the indicated antibodies: ACCα and phosphoACCα-
Ser79 (pACCα); 5′AMP-activated protein kinase alpha (AMPKα) and phosphoAMPKα-Thr172 
(pAMPKα) (Upstate); total serine/threonine kinase protein kinase B (AKT) and phospho AKT (pAKT) 
(Cell Signaling); β-actin (Sigma); FAS and CPT1A (Santa Cruz Biotechnology). For protein detection we 
used horseradish peroxidase-conjugated secondary antibodies and bands were visualized by enhanced 
chemiluminescence as instructed by the manufacturer (Amersham Biosciences). For quantification we 
applied ImageJ software based analysis (http://rsb.info.nih.gov/ij/). Protein levels were normalized to β-
actin for each sample. 
2.7. Enzyme and glycogen assays 
With the exception of CPT1 activity, which was analyzed in fresh tissue, all enzymatic assays were 
carried out with liver supernatants that were prepared as described above for Western blot assays. The 
reactions were started by the addition of homogenates (30 μl) and substrates (20 μl, omitted in controls) to 
the reaction mixture (final volume 250 μl), and the reactions were incubated at 37 °C for pre-established 
times (5–15 min). Enzyme activities were determined by spectrophotometry using a microplate reader 
(Tecan). FAS (Saggerson and Greenbaum, 1970), glucose-6-phosphate dehydrogenase (G6PDH), 6-
phosphogluconate dehydrogenase (6PGDH) (Tian et al., 1998 and Tian et al., 1999), CPT1 (Karlic et al., 
2002 and Shin et al., 2006), ATP citrate lyase (ACL) (Corrigan and Rider, 1983), glucokinase (GK), 
hexokinase (HK) (Davidson and Arion, 1987), fructose bisphosphatase (FBase) (Westbury and Hahn, 
1984) and pyruvate kinase (PK) (Denton et al., 1979) activities were measured using methods previously 
described. Glycogen levels in the liver extracts were determined as described by Keppler and Decker 
(1974). 
2.8. Statistical analysis 
Data are expressed as percentage of fed rats (control group) and presented as mean ± SEM and analyzed 
using SigmaStat 3.1 (Systat software, Inc.). Statistical significance was determined by one-way ANOVA 
with post hoc Student–Newman–Keuls test. p < 0.05 was considered significant. Different letters above 
bars indicate statistical significance. 
3. Results 
3.1. SPM NOX-B11(2) inhibits orexigenic effects of ghrelin 
In order to test the efficacy of NOX-B11(2) in neutralizing ghrelin's effect on food intake, we treated rats 
with Spiegelmer and AG as described under Section 2. As expected, pre-treatment with NOX-B11(2) 
blocked ghrelin-stimulated food intake, whereas the non-binding control SPM did not affect food intake 
induced by ghrelin (Fig. 2). Neither NOX-B11(2) nor control SPM altered food intake compared with 
animals treated with saline when administered without exogenous AG (data not shown). 
 
 
 
Fig. 2. Effect of an IP ghrelin treatment on cumulative food intake during 2 h following injection in rats (seven animals per group) 
treated previously with non-functional control SPM or NOX-B11(2). Values are expressed as mean ± SEM. Different letters 
indicate statistical significance (p < 0.05). 
  
3.2. Effect of NOX-B11(2) on body weight during fasting-refeeding cycle 
To determine the effects of ghrelin neutralization during refeeding rats were fasted and refed with or 
without treatment with NOX-B11(2) as described in Section 2 and body weight changes were recorded 
(Fig. 3). Body weight (BW) loss induced by fasting was unaffected by the neutralization of ghrelin. In 
contrast, treatment with NOX-B11(2) exerted a strong effect on the recovery of weight loss during the 
refeeding period. Animals treated with control Spiegelmer began to regain body weight 24 h after 
refeeding and this process continued until 48 h. In contrast, rats treated with NOX-B11(2) did not recover 
corporal weight after the refeeding until 48 h. This effect was not related to an inhibition of appetite as 
both treatment groups ingested all the food offered during the refeeding period. Thus, the inhibitory effect 
of NOX-B11(2) on body weight recuperation during refeeding following a 48 h period of food 
deprivation appears to be independent of food intake. 
 
 
 
Fig. 3. Effect of ghrelin neutralization on body weight change in fasted (48 h) and fasted (48 h)-refed (24 or 48 h) rats. Values are 
means ± SEM of eight animals per group. Different letters indicate statistical significance (p < 0.05). 
3.3. Effects of ghrelin neutralization during fasting-refeeding cycle on plasma parameters 
In order to further analyze the effects of ghrelin neutralization, various plasma parameters were examined 
(Fig. 4). As expected, 48 h after fasting plasma AG levels had increased significantly in rats treated with 
control SPM compared to the fed group. The AG levels decreased during refeeding, but did not return to 
the initial levels during the 48 h refeeding period. In rats treated with NOX-B11(2), fasting led to an even 
larger increase of AG levels and the increase did not diminish during the refeeding period (Fig. 4A). The 
tremendous increase in AG levels in animals treated with NOX-B11(2) is likely due to the presence of 
circulating AG–Spiegelmer complexes that are cleared more slowly, a finding that was reported 
previously (Shearman et al., 2006) and is typical for a drug binding to a ligand. 
  
 
 
 
Fig. 4. Plasma levels of acyl-ghrelin, insulin, glucose, triglycerides, lactate and GH in fed, fasted (48 h) and fasted (48 h)-refed (24 
or 48 h) rats treated with NOX-B11(2) or non-functional control SPM. Values are means ± SEM of eight animals per group. 
Different letters indicate statistical significance (p < 0.05). 
Plasma insulin levels decreased equally in both groups following fasting. However, after refeeding 
insulin levels in animals treated with NOX-B11(2) were lower than in animals injected with control SPM 
(Fig. 4B). Similarly, plasma glucose levels were decreased after fasting in both Spiegelmer treatment 
groups. During refeeding, only in the animals treated with NOX-B11(2) a significant increase in plasma 
glucose levels was observed (Fig. 4C). In both groups glucose and insulin levels remained significantly 
below the levels of fed animals and we believe that this fact is for the feeding regimen, since after 48 h of 
fasting the animals were subjected to caloric restriction. 
After 48 h of fasting, triglyceride (Fig. 4D) and lactate levels (Fig. 4E) were decreased in both 
experimental groups. During the refeeding period, plasma triglyceride levels in animals treated with 
control SPM recovered the values of fed rats within 24 h, while those treated with NOX-B11(2) remained 
lower even after 48 h of refeeding (Fig. 4D). Lactate levels increased slightly during the refeeding period 
in rats treated with NOX-B11(2) only (Fig. 4E), but the fasting-induced decline in lactate levels was not 
reversed in either treatment group during the refeeding period. As expected, 48 h after fasting plasma GH 
levels had decreased significantly in rats treated with control SPM and NOX-B11(2) compared to the fed 
group, however the decrease was lower in animals treated with NOX-B11(2). During the refeeding 
period, either group recovered the values of fed rats but those treated with NOX-B11(2) remained higher 
compared to control group even after 48 h of refeeding (Fig. 4F). 
3.4. Effects of ghrelin neutralization during fasting and refeeding cycle on liver glucose metabolism 
To assess the effect of AG neutralization during the fasting-refeeding cycle on glucose metabolism we 
analyzed the activity levels of enzymes involved in glucose metabolism. The results for several key 
enzymes of the glycolytic pathway are shown in Fig. 5A–C. Food deprivation clearly diminished activity 
levels of GK (Fig. 5A), HK (Fig. 5B) and PK (Fig. 5C). Activity levels of GK were strongly reduced 
following fasting in both experimental groups. After 24 h of refeeding the recovery of GK activity was 
similar in animals treated with NOX-B11(2) and control Spiegelmer. However, while GK activity in the 
NOX-B11(2) group returned to the level of fed animals after 48 h of refeeding, it did not recover in the 
control group (Fig. 5A). Activity levels of HK (Fig. 5B) and PK (Fig. 5C) were reduced following fasting 
in both animals treated with NOX-B11(2) and animals treated with control SPM. Following fasting there 
was significantly higher HK and PK activity for the NOX-B11(2) treatment group than the control 
Spiegelmer group, suggesting that ghrelin neutralization may have some protective effect on the activity 
of these enzymes during fasting. This effect disappeared during refeeding. No differences in HK and PK 
activities between control and NOX-B11(2) groups were observed following refeeding and the activity 
levels remained significantly below the levels of fed animals. 
 
 
 
Fig. 5. Hepatic activity levels of glucokinase (GK), hexokinase (HK), pyruvate kinase (PK), fructose bisphosphatase (Fbase) (A–D) 
and protein levels of total serine/threonine kinase protein kinase B AKT and pAKT (E–G) in fed, fasted (48 h) and fasted (48 h)-
refed (24 or 48 h) rats treated with NOX-B11(2) or control non-functional SPM. Values are means ± SEM of eight animals per 
group. Different letters indicate statistical significance (p < 0.05). 
  
Activity levels of FBPase (Fig. 5D), a key enzyme of gluconeogenesis, increased significantly during 
fasting in both experimental groups and diminished during refeeding. FBase activity during refeeding was 
moderately (but significantly) higher in animals in which ghrelin was neutralized. This suggests that 
ghrelin neutralization impairs the normal response of FBase activity during refeeding following fasting 
(Fig. 5D). 
Several studies relate the effects of ghrelin to changes in protein levels of serine/threonine kinase 
protein kinase B (AKT) and pAKT (Fig. 5E–G) (Baldanzi et al., 2002, Barazzoni et al., 2007, Chung et 
al., 2008 and Rossi et al., 2008). Moreover, in the liver, insulin controls both lipid and glucose 
metabolism through its cell surface receptor and intracellular mediators such as phosphatidylinositol 3-
kinase and serine-threonine kinase AKT. We observed that fasting caused a decrease in protein levels of 
phospho- (active) and total-AKT (Fig. 5E–G). Interestingly, after 48 h fasting the levels of pAKT were 
significantly less reduced in rats treated with NOX-B11(2), whereas reduction of total AKT levels was 
the same. In animals treated with the inactive control Spiegelmer both pAKT- and AKT-levels recovered 
to reach the levels of fed animals after 24 h of refeeding and these values did not change after 48 h of 
refeeding. In animals treated with NOX-B11(2) pAKT- and AKT-levels recovered to those of fed animals 
after 24 h of refeeding, but they decreased again after 48 h refeeding. 
To further investigate the role of AG during fasting and refeeding on hepatic glycemic reserves, 
glycogen levels were assessed (Fig. 6). The neutralization of AG did not affect the decrease in hepatic 
glycogen levels during fasting. However, after 24 and 48 h of refeeding, glycogen levels were lower in 
NOX-B11(2) treated animals compared with their controls. 
 
 
 
Fig. 6. Hepatic glycogen levels in fed, fasted (48 h) and fasted (48 h)-refed (24 or 48 h) rats treated with NOX-B11(2) or non-
functional control SPM. Values are means ± SEM of eight animals per group. Different letters indicate statistical significance 
(p < 0.05). 
3.5. Effects of ghrelin neutralization during fasting-refeeding cycle on the hepatic lipogenic pathway and 
the pentose phosphate pathway 
In order examine ghrelin function on hepatic lipogenesis during a fed-fasted-refed cycle, mRNA, protein 
and activity levels of enzymes involved in lipid synthesis were assessed in the different treatment groups. 
The levels of mRNA, protein and enzymatic activity of key enzymes involved in the regulation of lipid 
metabolism in liver are shown in Fig. 7. As expected, fasting markedly diminished mRNA levels of the 
fat storage promoting enzymes such as FAS, SCD-1, and ACCα in all animals, whether treated with 
NOX-B11(2) or not. However, after 24 h of refeeding, these enzymes’ expression increased to a greater 
extent in animals in which AG was not neutralized (Fig. 7A–C). Similarly, protein levels of FAS, ACCα 
and pACCα (Fig. 7D–F and I), and activity levels of FAS (Fig. 7J) and ACL (Fig. 7K) also decreased 
during fasting, but this decrease was less pronounced in animals treated with NOX-B11(2). Moreover, 
after 24 h of refeeding protein levels of FAS and ACCα and activity levels of FAS and ACL significantly 
increased in the control group over fasted animals, but not in the NOX-B11(2) group. However these 
enzymes (mRNA, protein or activity) did not show any differences between control group and animals 
treated with NOX-B11(2) after 48 h of refeeding. 
  
 
 
 
Fig. 7. Hepatic mRNA (A–C), protein (D–I) and activity levels (K–M) of lipid metabolism-related enzymes in fed, fasted (48 h) and 
fasted (48 h)-refed (24 or 48 h) rats treated with NOX-B11(2) or non-functional control SPM. Values are means ± SEM of eight 
animals per group. Different letters indicate statistical significance (p < 0.05). 
After 48 h of fasting, protein levels of pAMPKα and AMPKα (Fig. 7G–I) were significantly 
diminished in both groups. The decrease in AMPKα was lower in animals treated with NOX-B11(2) 
compared with the control group. 48 h after refeeding, protein levels of total AMPKα were further 
decreased in NOX-B11(2) treated animals. 
Fatty acid synthesis requires NADPH. It is produced by malic enzyme (ME) and via the pentose 
phosphate pathway by activation of G6PDH and 6PGDH. Interestingly, after 48 h of fasting, the 
enzymatic activities of G6PDH and 6PGDH exhibited a greater decrease in the animals treated with SPM 
control compared with those treated with NOX-B11(2). After 24 h of refeeding only the activity of 
6PGDH in control animals increased significantly (Fig. 7L and M). 
Overall, these data suggest a role of AG in hepatic inhibition/restoration of lipogenesis during fasting 
and refeeding cycle. 
3.6. Effects of ghrelin neutralization during fasting and refeeding cycle on liver β-oxidation 
We next examined levels of mRNA, protein and activity of CPT1A, an enzyme involved in lipid 
oxidation. The levels of mRNA for CPT1A increased during fasting and decreased with refeeding in both 
treatment groups. In animals treated with NOX-B11(2) the decrease of CPT1A mRNA levels appeared to 
recover more slowly during the first 24 h of refeeding compared to the control group, but both treatment 
groups exhibited the same levels after 48 h of refeeding (Fig. 8A). Protein levels of CPT1A decreased in 
fasted animals and recovered the values of the fed state after 24 h of refeeding in both treatment groups 
(Fig. 8B). Activity levels of CPT1A increased during fasting, independent of treatment. This increase 
persisted during the first 24 h of refeeding, but returned to the activity level of fed animals after 48 h of 
refeeding. 
 
 
 
Fig. 8. Hepatic mRNA (A), protein (B) and activity levels (E) of CPT1A, β-oxidation-related enzyme in fed, fasted (48 h) and fasted 
(48 h)-refed (24 or 48 h) rats treated with NOX-B11(2) or non-functional control SPM. Values are means ± SEM of eight animals 
per group. Different letters indicate statistical significance (p < 0.05). 
4. Discussion 
Our results provide a clear indication that ghrelin neutralization during the fasting-refeeding cycle impairs 
body weight recuperation and alters hepatic glucose and lipid metabolism. 
Since its identification ghrelin has received much attention due to its orexigenic and adipogenic 
effects, both in rodents and humans (Tschop et al., 2000 and Wren et al., 2001a). However, the 
observations that transgenic models and ghrelin knockout animals exhibit normal metabolic phenotypes 
make it difficult to pinpoint ghrelin's exact role in the control of appetite and body weight (Ariyasu et al., 
2005, Asakawa et al., 2005, Iwakura et al., 2005, Longo et al., 2008, Pfluger et al., 2008, Sun et al., 2003, 
Sun et al., 2006 and Sun et al., 2008). The findings that ghrelin levels are increased before food intake, 
during caloric restriction, body weight loss or anorexia, but decreased after food intake and obesity 
(Cummings et al., 2001, Cummings et al., 2002 and Shiiya et al., 2002) are in agreement with the 
hypothesis for ghrelin being part of a mechanism by which the organism senses changes in nutrient 
availability and triggers biological responses that modulate the efficiency of energy storage during 
periods of overflow or scarcity of nutrients. Such a model is supported by the observation that treatment 
with exogenous ghrelin increases expression and protein levels of lipogenic enzymes independently of 
any orexigenic effects (Theander-Carrillo et al., 2006). 
To test the hypothesis mentioned above, we analyzed if ghrelin neutralization during the fasting-
refeeding cycle alters metabolic pathways and energy storage in the liver. The main form of energy 
storage in liver is represented by glycogen and lipids. The origin of the stored lipids can be either the diet 
or de novo synthesis from carbohydrate through lipogenesis. Therefore, the major function of glycolysis 
in the liver is to provide the necessary glucose metabolites for de novo lipid synthesis (Foufelle and Ferre, 
2002). The effects of ghrelin neutralization on enzymes involved in glycolysis and lipogenesis 
(summarized in Fig. 9) were analyzed in this study. 
 
 
 
Fig. 9. Glycolytic and lipogenic pathways in the liver. 
Here, we demonstrated that ghrelin blockade during the fasting-refeeding cycle with a previously 
described AG-specific Spiegelmer compound (Shearman et al., 2006), impairs BW recuperation during 
refeeding. This result suggests a role for AG in the regulation of energy storage following a period of 
fasting. This finding is in agreement with previous studies in which on the one hand ghrelin neutralization 
was shown to lead to reduced energy efficiency and to ameliorate obesity in diet-induced obese mice 
(Shearman et al., 2006) and on the other hand it was demonstrated that treatment with ghrelin induces 
improved efficiency of food processing (Sangiao-Alvarellos et al., 2009 and Theander-Carrillo et al., 
2006). Ghrelin-mediated conservation of energy was shown to be mediated by down-regulation of 
thermogenesis, energy expenditure and spontaneous locomotor activity and these processes could help to 
explain the absence of body weight gain during refeeding when ghrelin was neutralized (Jaszberenyi et 
al., 2006, Tang-Christensen et al., 2004 and Theander-Carrillo et al., 2006). 
Another line of evidence in support of ghrelin's regulatory role in response to nutrient availability was 
provided in a study by Mayorov et al. in which mice treated with antibodies that hydrolyze the octanoyl 
moiety of ghrelin to form des-acyl-ghrelin showed greater whole body energy expenditure during fasting 
than untreated animals (Mayorov et al., 2008), suggesting that AG restrains energy expenditure during 
fasting. 
Our results indicate that the down-regulation of HK and PK activities, observed as a response to 
fasting, is mitigated by ghrelin neutralization. In addition, the protein and activity levels of enzymes 
related to lipid synthesis such as FAS, ACC and ATP citrate-lyase also exhibited higher levels during 
fasting in rats treated with NOX-B11(2) compared to control animals. Similarly, the reduction of 6PDGH 
and G6PDH activity, two important enzymes for the supply of NADPH for de novo lipogenesis, was also 
less pronounced by neutralization of AG during 24 h fasting (Kersten, 2001 and Salati and Amir-
Ahmady, 2001). Overall, these results suggest that blockade of ghrelin during prolonged fasting interferes 
with the normal down-regulation of the hepatic glycolytic pathway and ultimately of lipogenesis. Our 
findings illustrate ghrelin's importance during fasting as a key factor to promote the use of fat over 
glucose in all tissues where possible, and to provide glucose in sufficient amounts for glucose-dependent 
tissues such as the brain and erythrocytes. 
Many studies link the response to food deprivation/restriction to AMPKα as it is an energy sensing 
kinase which, once activated, promotes energy production and limits energy utilization to ensure cellular 
survival (Lage et al., 2008). These studies point to the possibility that AMPKα coordinates the changes in 
enzymes of lipid metabolism during the starved-refed transition (Assifi et al., 2005). It has been 
demonstrated that administration of ghrelin to rats affects AMPKα activity, although this effect is tissue-
specific. In the hypothalamus, central and peripheral ghrelin treatments enhance protein levels of AMPKα 
and this activation and alterations on lipid metabolism mediate the orexigenic effects of ghrelin 
(Andersson et al., 2004, Kohno et al., 2008, Kola et al., 2005, Kola et al., 2008 and Lopez et al., 2008). In 
fed animals peripheral chronic and acute ghrelin treatments provoked AMPKα activation in the heart, 
while in liver and adipose tissue it was inhibited and no effect was detected on skeletal muscle (Barazzoni 
et al., 2005 and Kola et al., 2005). In this work we showed that ghrelin neutralization caused lower 
AMPKα total protein levels after 48 h of refeeding compared with their controls, just like during 48 h of 
fasting. These results suggest that ghrelin's effects are dependent on the energetic status and that its 
neutralization during fasting and caloric restriction after fasting alters liver metabolism. The data 
demonstrate the importance of ghrelin in correct nutrient partitioning during negative energy balance. We 
show that the hepatic levels of pAMPKα and AMPKα are decreased after food deprivation in control 
SPM and NOX-B11(2) treated rats. However, it should be noted that the ratio of pAMPK to AMPK 
increased during fasting and decreased after refeeding in both groups (data not shown). 
During starvation, the central mechanism to provide the organism with glucose is de novo synthesis in 
the liver from precursors such as lactate, gluconeogenic amino acids, and glycerol. Likewise, when 
glucose is directly available from external sources, gluconeogenesis is dispensable and consequently 
needs to be shut off (Pilkis and Granner, 1992). Insulin is an anabolic hormone that in liver suppresses 
gluconeogenesis and activates lipogenesis during times of nutritional abundance through the activation of 
the insulin receptor (IR). Our data indicate that the drop in plasma insulin elicited by fasting is only 
partially restored following 24 h and 48 h of refeeding. Neutralization of ghrelin appears to have a 
significant inhibitory effect on the recovery of insulin levels during 48 h of refeeding. Moreover, FBPase 
levels increase during fasting but are suppressed during refeeding and the finding that FBPase levels are 
suppressed less in NOX-B11(2) treated animals is consistent with the effect of ghrelin neutralization on 
insulin levels during refeeding. 
When ghrelin was blocked, pAKT, a key protein kinase down-stream of IR (Brunet et al., 1999), 
exhibited a weaker down-regulation in response to fasting. The results could suggest that ghrelin 
neutralization during fasting enhances insulin sensitivity in liver, causing a lesser decrease in glucose 
uptake and consequently in glycolytic and glucogenic pathways. Previously, several works reported 
differences on insulin sensitivity in animals with deletions in the ghrelin and/or ghrelin receptor genes. 
Double knockout mice showed a trend towards improved glucose tolerance and insulin sensitivity after an 
overnight fast (Pfluger et al., 2008). Although these differences were not statistically significant, the 
findings are supported by independent studies that demonstrate that GHSR and ghrelin null mice display 
enhanced insulin sensitivity when subjected to caloric restriction or fasting (Sun et al., 2008). Recently 
Zhao et al. generated GOAT KO mice and they found that when these animals were subject to severe 
prolonged restriction caloric showed hypoglycemia compared with wild-type, contrary to results observed 
in this work. However, their caloric restriction was more severe (60%) and they only observed differences 
after 3 days of caloric restriction and when the blood was collected one-half hour before feeding. The 
authors suggested that GOAT activity and hence acyl-ghrelin levels, that enhanced in wild-type mice 
during calorie restriction, are necessaries for survival and maintenance of glucose levels of calorie 
restricted mice (Zhao et al., 2010). They observed that GH levels were significantly raised by prolonged 
caloric restriction however this increased is impaired in GOAT KO mice (Zhao et al., 2010). Their data 
reveal one essential relation between ghrelin and plasma GH levels during periods of severe calorie 
restriction, thereby assuring sufficient blood glucose to permit survival. In rats, food deprivation inhibits 
GH secretion (Muller et al., 1999) and in this study we observed that this decrease was lesser when acyl-
ghrelin was neutralized. Different works suggested that food deprivation in rats primarily reduces the 
activation of insulin signaling for glucose metabolism through reduction of GH and/or subsequent IGF-1 
signaling (Hayashi et al., 2008). The data obtained in our study and GOAT KO mice (Zhao et al., 2010) 
would reveal one function of ghrelin in maintenance of appropriate plasma GH levels during periods of 
fasting or food restriction. Recently Chiba et al. suggested a model where NPY and ghrelin play a crucial 
role during food deprivation in rats (Chiba et al., 2009). They proposed that caloric restriction decreased 
plasma insulin and leptin levels, whereas it increased ghrelin levels and that these hormonal changes 
result in an increased NPY expression in the arcuate nucleus. NPY/AgRP neurons project their axons to 
down-stream neurons such as GHRH neurons suppressing them. They also suggested that NPY up-
regulation could also enhance oxidative stress resistance and hepatic glucose production (Chiba et al., 
2009). In addition, intraventricular injection of NPY inhibited GH secretion, and a NPY antiserum led to 
elevated plasma GH levels and partially restored GH secretory pulses in food-deprived rats (Muller et al., 
1999). Acyl-ghrelin neutralization during food deprivation might do that the increase of the NPY was 
minor, which might explain a minor decrease in plasma GH levels and some of the changes observed in 
the hepatic metabolism, nevertheless further studies are necessary to demonstrate this theory. 
We did not observed changes in glucose levels during fasting in animals treated with NOX-B11(2) 
compared with their controls, although our results showed that neutralization of ghrelin during fasting 
contributes to incorrect inhibition of hepatic glycolysis and lipogenesis. Other studies with more 
prolonged fasting and caloric restrictions could to help to clarify these results. 
Insulin promotes the storage and synthesis of lipids, protein, and carbohydrates (Saltiel and Kahn, 
2001). The first step by which insulin increases energy storage or utilization involves the regulated 
transport of glucose into the cell (Chang et al., 2004) hence, lower insulin levels observed during 
refeeding in NOX-B11(2) treated rats could help explain lower level of hepatic glycogen and slightly 
higher glycemia that showed these animals. On the other hand, the insulin receptor substrate (IRS) 
proteins, initiates activation of the phosphatidylinositol 3-kinase pathway, resulting in stimulation of 
protein kinases such as AKT (Chang et al., 2004) that suppresses gluconeogenesis and activates glycogen 
synthesis via phosphorylation of FOXO1 (Zhang et al., 2002) and GSK-3 (Cross et al., 1995) 
respectively. Phosphorylation of GSK-3 inactivates GSK-3 kinase activity and leads to increased activity 
of glycogen synthetase (GS), resulting in enhanced glycogen deposition (Cross et al., 1995). For these 
reasons, the decrease in insulin levels and AKT phosphorylation after 48 h refeeding when ghrelin was 
blocked, could elucidate the decrease in glycogen levels present in the animals. However, further studies 
are necessary to clarify this hypothesis. 
In summary, our study delineates several lines of evidence that implicate ghrelin as an important 
regulator of the response to changes in energy availability: First, ghrelin neutralization during the fasting-
refeeding cycle interferes with normal recovery of body weight; second, the fasting-induced rise in 
ghrelin levels contributes to inhibition of hepatic glycolysis and lipogenesis, which appears to be linked to 
insulin sensitivity; and third, once food becomes available following the fasting, ghrelin promotes 
lipogenesis recovery and favors glycogen deposition in order to minimize negative effects from periods of 
food scarcity. 
The results point to ghrelin as a key player in regulating the enzymatic activities involved in restoring 
body weight following diet-induced weight loss. Ghrelin may thus be a relevant target in controlling the 
well-known phenomenon of patients quickly regaining weight that was lost in the course of a diet. 
Moreover, ghrelin manipulation could be therapeutically relevant to avoid refeeding syndrome, a 
potentially fatal clinical syndrome related to the treatment of malnutrition, which is associated with very 
low ghrelin levels (Korbonits et al., 2007). The understanding of ghrelin's role in the molecular 
mechanisms underlying the events that occur during fasting and refeeding will hopefully lead to new 
strategies for the design and development of suitable drugs for the treatment of pathologies of obesity, its 
co-morbidities, and other endocrine disorders affecting energy metabolism. 
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